The Role of Biomarkers in Upper Gastrointestinal Cancers
Canadian Oncology Today · 2025
DOI: 10.58931/cot.2025.2133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Nathalie Baudoux und 1 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Upper gastrointestinal (GI) cancers include esophageal, esophagogastric junction, and stomach cancers, which together represent the second leading cause of cancer-related mortality worldwide in both sexes, with approximately 1,100,000 deaths in 2022. The disease is usually diagnosed at an advanced non-curable stage, and conventional chemotherapy treatment is associated with poor prognosis. Advances have been made in the development of new therapies, including immunotherapy and targeted therapies. Biomarker identification has expanded treatment options and guides treatment selection. This article reviews the molecular characterization of GI cancers, which has been the subject of increasing research, and biomarker-targeted agents, representing a continually evolving landscape in upper GI cancers.
Zitieren
APA
Baudoux, N., & Aubin, F. (2025). The Role of Biomarkers in Upper Gastrointestinal Cancers. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2133
Vancouver
Baudoux N, Aubin F. The Role of Biomarkers in Upper Gastrointestinal Cancers. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2133
BibTeX
@article{Baudoux2025,
author = {Baudoux, Nathalie and Aubin, Francine},
title = {The Role of Biomarkers in Upper Gastrointestinal Cancers},
journal = {Canadian Oncology Today},
year = {2025},
doi = {10.58931/cot.2025.2133}
}
EUVIMED